Ozempic 2025. Ozempic, the blockbuster diabetes shot made by novo nordisk a/s, is “very likely” to be one of the next drugs to have its price slashed in bargaining with the us government, a. Novo nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose medicare prices will be negotiated in 2025 and go into effect in 2027, according to analysts and academics.
Diabetes medication to remain in short supply throughout 2025, manufacturer warns efforts to boost the production of ozempic (semaglutide) are not expected to alleviate. Novo nordisk, the pharmaceutical giant supplying ozempic, has alerted the therapeutic goods administration (tga) and the ozempic medicine shortage action group.